Boehringer Ingelheim Signs an Exclusive Worldwide License Agreement with Oncoheroes Biosciences for Volasertib

 Boehringer Ingelheim Signs an Exclusive Worldwide License Agreement with Oncoheroes Biosciences for Volasertib

Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

Shots:

  • Oncoheroes to get IP rights with an exclusive right to research, develop, sell and sublicense Boehringer’s Volasertib. Oncoheroes will further develop & commercialize volasertib for pediatric cancer indications
  • The license agreement allows Boehringer to continue the clinical development of volasertib to benefit pediatric patients with cancer
  • Volasertib is a Polo-like-kinase 1 inhibitor with strong clinical data supporting its development for rhabdomyosarcoma and a few other pediatric cancer indications. Boehringer developed Volasertib for a specific form of leukemia but it discontinued the clinical activities following the failure of P-III study in adults

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PharmaNews

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post